MS drug has fewer injection reactions

A new formulation of interferon beta-1a (Rebif) has been launched for relapsing remitting multiple sclerosis, which has a near three-fold reduction in injection-site reactions.



Sign in

In order to continue you need to be a registered user. If you would like to register to Nursing Times then click here.

Already Registered


Remember Me

New User?

If you are a new user and would like to register to Nursing Times then click here.



Register

Forgotten Password / Username

Enter your email *